A PHASE 3 SAFETY AND EFFICACY TRIAL OF FLT201 GENE THERAPY IN PATIENTS WITH GAUCHER DISEASE TYPE 1

Registry ID

FLT201-03

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

SPUR THERAPEUTICS LIMITED

Start date

2026-04-28

Last update

2025-12-23

Conditions

• GAUCHER DISEASE TYPE 1

Related clinical trials

• AN ADAPTIVE, OPEN-LABEL, MULTINATIONAL PHASE 1/2 STUDY OF THE SAFETY AND EFFICACY OF EX VIVO, LENTIVIRAL VECTOR-MEDIATED GENE THERAPY AVR-RD-02 FOR SUBJECTS WITH TYPE 1 GAUCHER DISEASE

View on source registry